NexgenRx Amends Debenture Terms and Confirms Extension of Warrants

NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") announces that
it has agreed to amend the terms of its currently outstanding convertible
debenture (the "Debenture"). The Debenture was issued in April 2012 in the
principal amount of $500,000 and was set to expire on November 26, 2013. The
Debenture has been amended to extend the maturity date to December 12, 2013 and
to amend the conversion price from $0.30 to $0.20 per common share. The TSX
Venture Exchange has approved these amendments to the terms of the Debenture.


In addition, the Corporation confirms that the TSX Venture Exchange has approved
its previously announced application to extend the term of all outstanding
common share purchase warrants granted pursuant to the Corporation's private
placement that closed on November 26, 2010 (the "Warrants") from thirty-six (36)
months to sixty (60) months from the date of issuance in accordance with
Exchange policies. The Warrants that are the subject of this extension consist
of an aggregate of 2,583,416 Warrants, each with an exercise price of $0.35 per
Warrant. The foregoing Warrants were set to expire on November 26, 2013 and the
expiry date has been extended to November 26, 2015.


About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design,
management and administration of health benefit plans offered by employers and
other plan sponsors for the benefit of their employees and plan members. More
information on NexgenRx can be found at www.nexgenrx.com.


Caution Regarding Forward-Looking Statements - This news release contains
certain forward-looking statements, including statements regarding the business
and anticipated financial performance of the Corporation. These statements are
subject to a number of risks and uncertainties. Actual results may differ
materially from results contemplated by the forward-looking statements. When
relying on forward-looking statements to make decisions, investors and others
should carefully consider the foregoing factors and other uncertainties and
should not place undue reliance on such forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
NexgenRx Inc.
Ronald C. Loucks
President and CEO
416.695.3393 ext. 801


NexgenRx Inc.
Taba Merrikh
Director of Finance
416-695-3393 ext. 803
www.nexgenrx.com